New MS drug trial aims to reduce brain lesions
NCT ID NCT06564311
Summary
This study is testing whether a new injectable medication called obexelimab can help control relapsing multiple sclerosis. It will involve 93 people with MS who will receive either the drug or a placebo for 12 weeks, followed by a longer period where everyone gets the drug. Researchers will primarily measure its effect on new brain lesions seen on MRI scans and monitor for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AZ Delta-Deltalaan 1
Roeselare, Belgium
-
Aalborg Universitetshospital
Aalborg, Denmark
-
Aqualine Clinical Research
Naples, Florida, 35105, United States
-
Attikon University General Hospital
Chaïdári, Greece
-
Barts Health NHS Trust
London, United Kingdom
-
Boster Center for MS
Columbus, Ohio, 43235, United States
-
Center for Neurological Disorders
Greenfield, Wisconsin, 53228, United States
-
Center for Neurology and Spine
Phoenix, Arizona, 85032, United States
-
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
-
Fondazione Isituto G. Giglio di Cefalu
Cefalù, Italy
-
Fondazione PTV Policlinico Tor Vergata
Roma, Italy
-
General University Hospital Praha
Prague, Czechia
-
Holy Name Medical Center
Teaneck, New Jersey, 07666, United States
-
Hospipal La Fe Valencia
Valencia, Spain
-
Hospital Clinico San Carlos
Madrid, Spain
-
Hospital General Universitario Gregorio Marañon
Madrid, Spain
-
Hospital Regional Universitario de Malaga
Málaga, Spain
-
Hospital Regional Universitario de Malaga - Hospital General
Málaga, Spain
-
Hospital Universitario Virgen de La Arrixaca
Murcia, Spain
-
Hospital Virgen Macarena
Seville, Spain
-
Infusion Associates Plymouth
Plymouth, Minnesota, 55446, United States
-
Istituto Neurologico Mediterraneo Neuromed
Pozzilli, Italy
-
Klinicki bolnicki centar Zagreb
Zagreb, Croatia
-
Leicester General Hospital
Leicester, United Kingdom
-
M.A. LEK A.M. Maciejowsy Spolka Cywilna
Katowice, Poland
-
MS Center for Innovations in Care
St Louis, Missouri, 63131, United States
-
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
-
Morriston Hospital
Swansea, United Kingdom
-
Nemocnice Jihlava
Jihlava, Czechia
-
Neuro-logisch Wien
Vienna, Austria
-
Neurocentrum Bydgoszcz sp.z o.o.
Bydgoszcz, Poland
-
North Central Neurology
Cullman, Alabama, 35058, United States
-
North Texas Institute of Neurology and Headache
Plano, Texas, 75024, United States
-
People's Hospital of Xinjiang Uyaur Autonomous Region
Ürümqi, China
-
Perseverance Research Center
Scottsdale, Arizona, 85253, United States
-
Regina Berkovich MD PhD, Inc
West Hollywood, California, 90048, United States
-
Rehabilitation & MS Center, Noorderhart Hospital
Overpelt, Belgium
-
The First Affiliation Hospital of Soochow University
Suzhou, China
-
Tianjin Medical University General Hospital
Tianjin, China
-
Tiantan Hospital, Capital Medical University
Beijing, China
-
Tongji Hospital, Tongji Medical Center of HUST
Wuhan, China
-
University General Hospital of Larissa
Larissa, Greece
-
University of Florence
Florence, Italy
-
University of Massachusetts Medical School
Worcester, Massachusetts, 01655, United States
-
University of South Florida
Tampa, Florida, 33620, United States
-
Wielospecjalistyczne Centrum Medyczne Ibismed
Zabrze, Poland
-
Zanamed Medical Clinic Sp z o.o.
Lublin, Poland
Conditions
Explore the condition pages connected to this study.